Table 1.

Summary of AML cases

Characteristic	Case 1	Case 2
Age, y	71	68
Performance status (ECOG)	1	2
WHO/FAB Dx	AML M0	AML M2
Prior AML therapy	No	FLAG chemotherapy at original presentation
Duration of prior remission	N/A	3.5 y
Lenalidomide treatment
Cycle 1	50 mg/d, days 1-14; no therapy × 30 d	35 mg/d, days 1-21
Cycle 2	50 mg/d × 21 d; no therapy × 30 d	35 mg days 1-4 (therapy halted due to pneumonia)
Cycle 3		35 mg days 1-21
Cycle 4		(start of cycle delayed 3 wk until resolution of grade 2* neutropenia and thrombocytopenia) 35 mg days 1-21
Low-dose cycles	10 mg/d, days 1-28, × 5; then low-dose therapy 10 mg/d, ongoing
Prelenalidomide data
White blood cells	1900/μL	1700/μL
Hemoglobin	6.7 g/dL	9.3 g/dL
Platelets	74 000/μL	45 000/μL
ANC	190/μL	530/μL
PB blast	363/μL (33%)	0/μL
BM cellularity	30%	40%
BM blasts	90%	40%
Karyotype	47,XY,+13[5]/46,XY[15]	94<4n>,XXYY,+13,+13(cp15)/46,XY(3)/nonclonal(2)
Data at CR
Days to CR	124 (35 d of high-dose therapy, 28 d of low-dose therapy)	78 (25 d of treatment)
White blood cells	6100/μL	7500/μL
Hemoglobin	10.1 g/dL	8.6 g/dL
Platelets	231 000/μL	210 000/μL
ANC	4148/μL	4275/μL
BM cellularity	60%	40%
BM blast	< 5%	<5%
Duration of CR	9 mo	9 mo
CR confirmation	Yes (6 wk, 16 wk)	Yes (5 wk)

WHO indicates World Heath Organization; ECOG, Eastern Cooperative Oncology Group; Dx, diagnosis; ANC, absolute neutrophil count; PB, peripheral blood; BM, bone marrow; and CR, complete remission.

^*Toxicity graded by National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0.